Research
Hormonal
Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).
Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.
StrongSupportsmedium confidence
The mean change in the WOMAC pain score at week 68 was -41.7 points with semaglutide and -27.5 points with placebo (P<0.001).
Why this rating
Based on a large randomized controlled trial design.
Source
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal et al. · New England Journal of Medicine · 2024
rct · n=407Cited 306×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →